Orthocell Limited (ASX:OCC) Reports First US Remplir™ Sales Revenue
Orthocell (ASX:OCC) records first US sales revenue from Remplir™ nerve repair product, marking a significant milestone in US expansion.
Orthocell (ASX:OCC) records first US sales revenue from Remplir™ nerve repair product, marking a significant milestone in US expansion.
Mach7 Technologies (ASX:M7T) updates its FY25 guidance, initiates a share buyback, and announces an investor webinar with the new CEO.
Biome Australia Limited (ASX:BIO) reports a 41% revenue increase in FY25, highlighting strong performance in Q4 and June.
Botanix Pharmaceuticals (ASX:BOT) reports $25M AUD in Sofdra™ sales and expansion of prescriber network, signaling strong market performance.
Nova Eye Medical Limited (ASX:EYE) reports record FY25 revenues of A$28.8m, driven by strong US sales and highest Q4 sales on record.
Nanosonics Limited (ASX:NAN) launches trophon3 and trophon2 Plus, enhancing infection prevention with faster disinfection and advanced digital integration.
Imugene Limited (ASX:IMU) receives a A$5.8m R&D tax refund to advance its immuno-oncology pipeline.
OncoSil Medical (ASX:OSL) completes patient recruitment for the PANCOSIL study, advancing its clinical development of pancreatic cancer treatment.
BCAL Diagnostics Limited (ASX:BDX) partners with Cancer Care Associates to accelerate adoption of BREASTEST plus™ in breast cancer diagnostics.
Pro Medicus Limited (ASX:PME) signs a A$170M, 10-year contract with UCHealth to implement its Visage 7 imaging platform.